The effectiveness of parasympathomimetics for treating underactive bladder: A systematic review and meta‐analysis

@article{Moro2021TheEO,
  title={The effectiveness of parasympathomimetics for treating underactive bladder: A systematic review and meta‐analysis},
  author={Christian Moro and Charlotte Phelps and Vineesha Veer and Justin Clark and Paul P. Glasziou and Kari A. O. Tikkinen and Anna Mae Scott},
  journal={Neurourology and Urodynamics},
  year={2021},
  volume={41},
  pages={127 - 139}
}
Biological rationale suggests that parasympathomimetics (cholinergic receptor stimulating agents) could be beneficial for patients with underactive bladder. However, no systematic review with meta‐analysis addressing potential benefits or adverse effects exists. The aim of this review was to assess the effectiveness, both benefits and harms, of using parasympathomimetics for the treatment of underactive bladder. 

Therapeutic effects of silodosin and urapidil on underactive bladder associated with diabetic cystopathy

This work investigated the effects of silodosin (alpha1A‐AR antagonists) and urapidil (nonselective alpha1‐AR antagonist) on the voiding function in female rats with diabetes mellitus (DM).

The Dependence of Urinary Bladder Responses on Extracellular Calcium Varies Between Muscarinic, Histamine, 5-HT (Serotonin), Neurokinin, Prostaglandin, and Angiotensin Receptor Activation

Although the specific requirement ofCa2+ on contractile responses varies depending on the receptor, extracellular Ca2+ plays a key role in mediating G protein-coupled receptor contractions of the urothelium and lamina propria.

References

SHOWING 1-10 OF 38 REFERENCES

Is the use of parasympathomimetics for treating an underactive urinary bladder evidence‐based?

It is concluded that the available studies do not support the use of parasympathomimetics for treating UUB, specifically when frequent and/or serious possible side‐effects are taken into account.

Updates of underactive bladder: a review of the recent literature

In this review, the current terminology, epidemiology, physiopathology, evaluation, and management of UAB are discussed.

Addressing challenges in underactive bladder: recommendations and insights from the Congress on Underactive Bladder (CURE-UAB)

A series of workshops aimed to define UAB and its phenotype, define detrusor underactivity (DU) and create a subtyping of DU, evaluate existing animal models for DU, and establish research priorities for UAB.

Current pharmacological and surgical treatment of underactive bladder

  • D. Kim
  • Medicine
    Investigative and clinical urology
  • 2017
Although surgery to reduce outlet resistance may be a viable option in UAB with presumed obstruction, surgery seems to have little role in those without obstruction, current treatments of UAB remain unsatisfactory.

Is coexistent overactive–underactive bladder (with or without detrusor overactivity and underactivity) a real clinical syndrome? ICI‐RS 2019

Lower urinary tract symptoms (LUTS) can be classified into symptom syndromes based on which symptoms are predominant, and sometimes OAB and UAB can coexist in the same patient and, if so, need a specific approach beyond treatment of the single and apparently opposing syndrome.

Pathophysiological mechanisms in detrusor underactivity: Novel experimental findings

It is shown that afferent dysfunction, such as altered expression of muscarinic and purinergic P2X3 receptors or diminished urothelial ATP may play a role in the initial and reversible stages of DU, with potential diagnostic and therapeutic implications.

Management of Urinary Incontinence With Underactive Bladder: A Review

When voiding dysfunction occurs after incontinence treatment with UAB, voiding symptoms can be improved by various therapeutic modalities, and patients' quality of life can be further degraded.